BCM
WHWK

Bridgeway Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Bridgeway Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$743K Hold
215,284
– – 0.01% 759
2025
Q4 		$521K Hold
215,284
– – 0.01% 813
2025
Q3 		$409K Sell
215,284
-100,000
-32% -$184K 0.01% 846
2025
Q2 		$590K Hold
315,284
– – 0.01% 746
2025
Q1 		$561K Buy
315,284
+199,884
+173% +$522K 0.01% 728
2024
Q4 		$364K Buy
115,400
+22,100
+24% +$50.1K 0.01% 880
2024
Q3 		$192K Buy
+93,300
New +$151K ﹤0.01% 1076

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Bridgeway Capital Management's WHWK Position: Q1 2026 in Review

Bridgeway Capital Management held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 215,284 shares worth $743K. The position accounts for 0.01% of the portfolio, ranked #759.

Bridgeway Capital Management first reported a position in WHWK in Q3 2024 and has held it in 7 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Bridgeway Capital Management held 215,284 shares of Whitehawk Therapeutics worth $743K as of Q1 2026.
  • Bridgeway Capital Management left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #759 holding.
  • Bridgeway Capital Management first reported a position in Whitehawk Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.